NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
NCT01451515
Completed
This is a phase II clinical trial using risk-adapted therapy. The treatment is acute lymphoblastic leukemia (ALL)-based therapy, using multi-agent regimens comprising of induction, consolidation, and continuation (maintenance) phases delivered over 24-30 months. Participants will be classified into 3 treatment stratums, based on bone marrow/peripheral blood lymphoma cells involvement at diagnosis and day 8 for T-lymphoblastic lymphoma and bone marrow/peripheral blood lymphoma cells involvement a... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
06/07/2022
Locations: Rady Children's Hospital San Diego, San Diego, California
Conditions: Lymphoblastic Lymphoma
Register for Updates
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
NCT02999854
Terminated
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic malignancy. An additional objective of the study is to compare the effect of the two treatments on quality of life.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/28/2022
Locations: City of Hope National Medical Center, Duarte, California +3 locations
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Register for Updates
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
NCT02043587
Terminated
The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/26/2022
Locations: UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center, La Jolla, California +3 locations
Conditions: Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Register for Updates
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00887536
Completed
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this stud... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
04/13/2022
Locations: Central Hematology/Oncology Medical Group, Inc., Alhambra, California +49 locations
Conditions: Breast Cancer
Register for Updates
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NCT01547741
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2022
Locations: Kaiser Anaheim Medical Center, Anaheim, California +66 locations
Conditions: Breast Cancer
Register for Updates
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
NCT00567567
Completed
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments before a... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/01/2022
Locations: Kaiser Permanente Downey Medical Center, Downey, California +15 locations
Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
NCT01026220
Completed
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/01/2022
Locations: Southern California Permanente Medical Group, Downey, California +12 locations
Conditions: Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
NCT03836352
Active Not Recruiting
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2022
Locations: Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center, Los Angeles, California
Conditions: Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
Register for Updates
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
NCT01724866
Completed
The purpose of this study is to assess the effect of test doses of SPI-2012 on the duration of severe neutropenia (DSN) during Cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2022
Locations: California Cancer Associates for Research and Excellence, Fresno, California +3 locations
Conditions: Neutropenia
Register for Updates
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
NCT02293109
Completed
This phase I trial studies the side effects and best dose of carfilzomib when given together with the hyperfractionated (hyper)-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (CVAD) chemotherapy regimen in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfat... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/08/2022
Locations: University of California Davis, Sacramento, California
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
Register for Updates
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
NCT02643420
Completed
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of severe neutropenia (DSN) in Cycle 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: Pacific Cancer Medical Center, Inc., Anaheim, California +14 locations
Conditions: Neutropenia, Breast Cancer
Register for Updates
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
NCT02953340
Completed
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: Pacific Cancer Medical Center, Inc., Anaheim, California +7 locations
Conditions: Neutropenia, Breast Cancer
Register for Updates